Genetic testing for Lynch Syndrome prevents cancers being missed
Genetic testing for Lynch Syndrome must increase to prevents cancers being missed
Related Articles
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
FDA Approves Acalabrutinib Plus Bendamustine and Rituximab for Previously Untreated MCL
The FDA has approved acalabrutinib plus bendamustine and rituximab for adult patients with previously untreated MCL who are ineligible for autologous HSCT.
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live Longer | Cancer Today
Recent findings support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months.
FDA Approves Acalabrutinib With Bendamustine and Rituximab for Frontline MCL | Blood Cancers Today
In the phase 3 ECHO trial, acalabrutinib with bendamustine and rituximab reduced the risk of disease progression or death by 27% compared with standard-of-care chemoimmunotherapy.
Evaluating a CNS-Penetrant EGFR Inhibitor in Brain Cancer
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Cervical Cancer Screening: Somatic Mutations
Investigators in the Clinical Genetics Branch, led by senior investigator Lisa Mirabello and former research fellow Maísa Pinheiro, used deep targeted sequencing to look for…
Beta papillomaviruses: From foe to friend in skin cancer immunity
In this issue of Cancer Cell, Son et al. highlight an unexpected role for skin β-papillomaviruses in the protection against skin carcinogenesis. T cell immunity to skin…
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received…
